A2Aantagonists as novel non-dopaminergic therapy for motor dysfunction in PD
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The future management of Parkinson's disease (PD) requires pharmacologic agents that do not lose efficacy with disease progression or induce dyskinesia and that are free of other dopaminergic side effects. A2A receptor antagonists may provide an opportunity to introduce nondopaminergic management of PD. A2A receptors are selectively localized in basal ganglia and to the indirect output pathway where they control GABA and acetylcholine release. The A2A antagonists are effective in rodent models of PD, reversing motor deficits in haloperidol-treated, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated, or reserpinized mice, and potentiating L-dopa-induced rotation in 6-hydroxydopamine-lesioned rats without inducing dyskinesia. Importantly, the selective A2A antagonist KW6002 reverses motor disability and increases locomotor activity in MPTP-treated primates without provoking dyskinesia established by previous exposure to L-dopa. In addition, KW6002 shows additive antiparkinsonian activity with L-dopa and the D2 agonist quinpirole in MPTP-treated primates without enhancing the intensity of dyskinesia. The data available suggest that A2A antagonists, such as KW6002, may be effective as monotherapy for the management of PD and that they will also produce additional benefit when administered in combination with L-dopa or dopamine agonist therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
Nomenclature and classification of purinoceptors.
Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., & Williams, M. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06782-1 · Cited by 1,585
Cited by
Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits
Salamone, J. D., Correa, M., Farrar, A., & Mingote, S. M. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0668-9 · Cited by 1,000
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
“disability and do not worsen dyskinesia [224,228–231].”
Striatal mechanisms underlying movement, reinforcement, and punishment
Kravitz, A. V., & Kreitzer, A. C. (2012) · Physiology · doi:10.1152/physiol.00004.2012 · Cited by 224
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Metadata
- Authors
- Jenner, P.
- Venue
- Neurology
- Published
- 2003-12-09
- Volume
- 61
- Issue
- 11_suppl_6
- Pages
- S32-8
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2014175065
- Cited by
- 101
- References
- 3
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A2Aantagonists as novel non-dopaminergic therapy for motor dysfunction in PD. https://app.cochat.ai/papers/10.1212/01.wnl.0000095209.59347.79
- The paper
- Jenner, P. (2003). A2Aantagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology. https://doi.org/10.1212/01.wnl.0000095209.59347.79
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.